H.C. Wainwright analyst Joseph Pantginis downgraded Panbella Therapeutics (NASDAQ: PBLA) from Buy to Neutral.The analyst comments "Yesterday after the close ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades

Form 424B3 Panbela Therapeutics, May 16, 2024 6:04 AM Form 424B3 Panbela Therapeutics, May 16, 2024 6:04 AM Form 424B3 Panbela Therapeutics, May 16, 2024 6:04 AM Form 424B3 Panbela Therapeutics, May 16, 2024 6:03 AM Form 424B3 Panbela Therapeutics, May 16, 2024 6:03 AM Form 424B3 Panbela Therapeutics, May 16, 2024 6:03 AM Form 424B3 Panbela Therapeutics, May 16, 2024 6:03 AM Panbela Therapeutics, Inc. (PBLA) Tops Q1 EPS by 132cMay 15, 2024 4:41 PM Form 10-Q Panbela Therapeutics, For: Mar 31May 15, 2024 4:33 PM Form 8-K Panbela Therapeutics, For: May 15May 15, 2024 4:18 PM Panbela Provides Business Update and Reports Q1 2024 Financial ResultsMay 15, 2024 4:10 PM